BioCentury
ARTICLE | Company News

Merck, Aralez deal

September 12, 2016 7:00 AM UTC

Aralez purchased U.S. and Canadian rights to Zontivity vorapaxar from Merck. The protease-activated receptor 1 (PAR1) antagonist that inhibits thrombin-induced platelet activation is approved to red...